{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:08Z","timestamp":1790285948473,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-026-02872-z","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T07:56:49Z","timestamp":1771315009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antithrombotic therapy for cancer-associated venous thromboembolism"],"prefix":"10.1007","author":[{"given":"Giacinto","family":"Di Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza Agata","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"1","key":"2872_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W et al (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8(1):11","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2872_CR2","first-page":"483","volume":"10","author":"J Grudeva-Popova","year":"2005","unstructured":"Grudeva-Popova J (2005) Cancer and venous thromboembolism. J BUON 10(4):483\u2013489","journal-title":"J BUON"},{"key":"2872_CR3","doi-asserted-by":"publisher","unstructured":"Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP et al (2019) Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 28(151):180119. https:\/\/doi.org\/10.1183\/16000617.0119-2018","DOI":"10.1183\/16000617.0119-2018"},{"issue":"6","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M (2023) Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost 21(6):1397\u20131408","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2872_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.19414","volume":"205","author":"R Alikhan","year":"2024","unstructured":"Alikhan R, Gomez K, Maraveyas A, Noble S, Young A, Thomas M et al (2024) Cancer-associated venous thrombosis in adults (second edition): a British Society for Haematology guideline. Br J Haematol 205(1):71\u201387","journal-title":"Br J Haematol"},{"key":"2872_CR6","doi-asserted-by":"publisher","unstructured":"Tsantes AG, Petrou E, Tsante KA, Sokou R, Frantzeskaki F, Domouchtsidou A et al (2024) Cancer-associated thrombosis: pathophysiology, laboratory assessment, and current guidelines. Cancers (Basel) 16(11). https:\/\/doi.org\/10.3390\/cancers16112082","DOI":"10.3390\/cancers16112082"},{"issue":"2","key":"2872_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/CCO.0000000000001125","volume":"37","author":"I Mahe","year":"2025","unstructured":"Mahe I, Benarroch S, Djennaoui S, Hakem R, Ghorbel A, Helfer H et al (2025) Cancer-associated thrombosis: what is new? Curr Opin Oncol 37(2):150\u2013157","journal-title":"Curr Opin Oncol"},{"issue":"14","key":"2872_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horvath-Puho E, van Es N, van Laarhoven HWM, Pedersen L, Moik F et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959\u20131969","journal-title":"Blood"},{"issue":"2","key":"2872_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0767-5","volume":"21","author":"HK Patel","year":"2019","unstructured":"Patel HK, Khorana AA (2019) Anticoagulation in cancer patients: a summary of pitfalls to avoid. Curr Oncol Rep 21(2):18","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2872_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1160\/TH15-08-0686","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57\u201365","journal-title":"Thromb Haemost"},{"issue":"29","key":"2872_CR11","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","volume":"27","author":"AA Khorana","year":"2009","unstructured":"Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839\u20134847","journal-title":"J Clin Oncol"},{"issue":"2","key":"2872_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/TH16-08-0615","volume":"117","author":"C Ay","year":"2017","unstructured":"Ay C, Pabinger I, Cohen AT (2017) Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 117(2):219\u2013230","journal-title":"Thromb Haemost"},{"issue":"6","key":"2872_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","volume":"49","author":"AJ Walker","year":"2013","unstructured":"Walker AJ, Card TR, West J, Crooks C, Grainge MJ (2013) Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 49(6):1404\u20131413","journal-title":"Eur J Cancer"},{"issue":"7","key":"2872_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","volume":"103","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, Sondergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J et al (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997\u20132006. Br J Cancer 103(7):947\u2013953","journal-title":"Br J Cancer"},{"issue":"8","key":"2872_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","volume":"98","author":"B Dickmann","year":"2013","unstructured":"Dickmann B, Ahlbrecht J, Ay C, Dunkler D, Thaler J, Scheithauer W et al (2013) Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 98(8):1309\u20131314","journal-title":"Haematologica"},{"key":"2872_CR16","doi-asserted-by":"crossref","unstructured":"da Costa WL, Jr., Guffey D, Oluyomi A, Bandyo R, Rosales O, Wallace CD et al (2022) Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. Am J Hematol 97(8):1044\u201354","DOI":"10.1002\/ajh.26623"},{"issue":"10","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339\u20132346","journal-title":"Cancer"},{"issue":"1","key":"2872_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","volume":"243","author":"G Agnelli","year":"2006","unstructured":"Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89\u201395","journal-title":"Ann Surg"},{"issue":"3","key":"2872_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119(3):648\u2013655","journal-title":"Cancer"},{"issue":"19","key":"2872_CR20","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277\u20132285","journal-title":"JAMA"},{"key":"2872_CR21","doi-asserted-by":"publisher","unstructured":"Wang TF, Khorana AA, Carrier M (2021) Thrombotic complications associated with immune checkpoint inhibitors. Cancers (Basel) 13(18):4606. https:\/\/doi.org\/10.3390\/cancers13184606","DOI":"10.3390\/cancers13184606"},{"issue":"21","key":"2872_CR22","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","volume":"168","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH (2008) Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168(21):2377\u20132381","journal-title":"Arch Intern Med"},{"issue":"2","key":"2872_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMp030086","volume":"349","author":"RL Bick","year":"2003","unstructured":"Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349(2):109\u2013111","journal-title":"N Engl J Med"},{"issue":"2","key":"2872_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2018","unstructured":"Johnstone C, Rich SE (2018) Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 7(2):265\u2013273","journal-title":"Ann Palliat Med"},{"issue":"4","key":"2872_CR25","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","volume":"105","author":"JL Yu","year":"2005","unstructured":"Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI et al (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105(4):1734\u20131741","journal-title":"Blood"},{"issue":"1","key":"2872_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jth.13181","volume":"14","author":"JE Geddings","year":"2016","unstructured":"Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R et al (2016) Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14(1):153\u2013166","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2872_CR27","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1538-7836.2008.02987.x","volume":"6","author":"M Davila","year":"2008","unstructured":"Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J et al (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 6(9):1517\u20131524","journal-title":"J Thromb Haemost"},{"key":"2872_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","volume":"225","author":"AS Kim","year":"2020","unstructured":"Kim AS, Khorana AA, McCrae KR (2020) Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 225:33\u201353","journal-title":"Transl Res"},{"issue":"2","key":"2872_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5482\/ha-1160","volume":"32","author":"F Langer","year":"2012","unstructured":"Langer F, Bokemeyer C (2012) Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie 32(2):95\u2013104","journal-title":"Hamostaseologie"},{"key":"2872_CR30","doi-asserted-by":"crossref","unstructured":"Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102 Suppl 1(Suppl 1):S2\u20139","DOI":"10.1038\/sj.bjc.6605599"},{"issue":"10","key":"2872_CR31","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","volume":"13","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC et al (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13(10):2870\u20132875","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2872_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA (2021) Venous and arterial thromboembolism in patients with cancer: JACC: cardioOncology state-of-the-art review. JACC CardioOncol 3(2):173\u2013190","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2872_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5482\/HAMO-13-10-0054","volume":"34","author":"J Riedl","year":"2014","unstructured":"Riedl J, Pabinger I, Ay C (2014) Platelets in cancer and thrombosis. Hamostaseologie 34(1):54\u201362","journal-title":"Hamostaseologie"},{"issue":"7","key":"2872_CR34","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","volume":"112","author":"C Ay","year":"2008","unstructured":"Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703\u20132708","journal-title":"Blood"},{"issue":"3","key":"2872_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.seminoncol.2014.04.009","volume":"41","author":"GC Connolly","year":"2014","unstructured":"Connolly GC, Phipps RP, Francis CW (2014) Platelets and cancer-associated thrombosis. Semin Oncol 41(3):302\u2013310","journal-title":"Semin Oncol"},{"issue":"5663","key":"2872_CR36","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al (2004) Neutrophil extracellular traps kill bacteria. Science 303(5663):1532\u20131535","journal-title":"Science"},{"issue":"10","key":"2872_CR37","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"1","key":"2872_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1677040","volume":"45","author":"E Laridan","year":"2019","unstructured":"Laridan E, Martinod K, De Meyer SF (2019) Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 45(1):86\u201393","journal-title":"Semin Thromb Hemost"},{"key":"2872_CR39","doi-asserted-by":"crossref","unstructured":"Lam FW, Cruz MA, Parikh K, Rumbaut RE (2016) Histones stimulate von Willebrand factor release in vitro and in vivo. Haematologica 101(7):e277\u2013e279","DOI":"10.3324\/haematol.2015.140632"},{"issue":"8","key":"2872_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm.2184","volume":"16","author":"S Massberg","year":"2010","unstructured":"Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C et al (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16(8):887\u2013896","journal-title":"Nat Med"},{"issue":"22","key":"2872_CR41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/eurheartj\/ehv007","volume":"36","author":"DA Stakos","year":"2015","unstructured":"Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S et al (2015) Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J 36(22):1405\u20131414","journal-title":"Eur Heart J"},{"issue":"1","key":"2872_CR42","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1038\/s41598-017-06893-7","volume":"7","author":"AC Leal","year":"2017","unstructured":"Leal AC, Mizurini DM, Gomes T, Rochael NC, Saraiva EM, Dias MS et al (2017) Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep 7(1):6438","journal-title":"Sci Rep"},{"issue":"4","key":"2872_CR43","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-03-0198","volume":"10","author":"FL Sciacca","year":"2004","unstructured":"Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S et al (2004) Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10(4):1312\u20131317","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2872_CR44","first-page":"943","volume":"24","author":"GP Sotiropoulos","year":"2019","unstructured":"Sotiropoulos GP, Kotopouli M, Karampela I, Christodoulatos GS, Antonakos G, Marinou I et al (2019) Circulating plasminogen activator inhibitor-1 activity: a biomarker for resectable non-small cell lung cancer? J BUON 24(3):943\u2013954","journal-title":"J BUON"},{"issue":"20 Suppl 6","key":"2872_CR45","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.2146\/ajhp060389","volume":"63","author":"J Edelsberg","year":"2006","unstructured":"Edelsberg J, Hagiwara M, Taneja C, Oster G (2006) Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health Syst Pharm 63(20 Suppl 6):S16-22","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"2872_CR46","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347","journal-title":"Lancet Oncol"},{"issue":"7","key":"2872_CR47","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","volume":"110","author":"A Leizorovicz","year":"2004","unstructured":"Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110(7):874\u2013879","journal-title":"Circulation"},{"key":"2872_CR48","doi-asserted-by":"crossref","unstructured":"Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341(11):793\u2013800","DOI":"10.1056\/NEJM199909093411103"},{"issue":"7537","key":"2872_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","volume":"332","author":"AT Cohen","year":"2006","unstructured":"Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332(7537):325\u2013329","journal-title":"BMJ"},{"key":"2872_CR50","doi-asserted-by":"crossref","unstructured":"Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127(1):82\u20136.e1","DOI":"10.1016\/j.amjmed.2013.09.015"},{"issue":"10","key":"2872_CR51","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","volume":"4","author":"JI Zwicker","year":"2020","unstructured":"Zwicker JI, Roopkumar J, Puligandla M, Schlechter BL, Sharda AV, Peereboom D et al (2020) Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv 4(10):2254\u20132260","journal-title":"Blood Adv"},{"key":"2872_CR52","unstructured":"(NCCN) NCCN. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease plymouth meeting, PA: National Comprehensive Cancer Network; 2025 [Version 3.2025:[Available from:  https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1423"},{"key":"2872_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072715","volume":"381","author":"SR Guntupalli","year":"2023","unstructured":"Guntupalli SR, Spinosa D, Wethington S, Eskander R, Khorana AA (2023) Prevention of venous thromboembolism in patients with cancer. BMJ 381:e072715","journal-title":"BMJ"},{"issue":"8","key":"2872_CR54","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004118","volume":"5","author":"S Osataphan","year":"2021","unstructured":"Osataphan S, Patell R, Chiasakul T, Khorana AA, Zwicker JI (2021) Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv 5(8):2055\u20132062","journal-title":"Blood Adv"},{"issue":"4","key":"2872_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"issue":"5","key":"2872_CR56","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F et al (2023) Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol 34(5):452\u2013467","journal-title":"Ann Oncol"},{"issue":"16","key":"2872_CR57","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063\u20133071","journal-title":"J Clin Oncol"},{"issue":"41","key":"2872_CR58","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"7","key":"2872_CR59","first-page":"CD009447","volume":"7","author":"CF Matar","year":"2018","unstructured":"Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosuico VE et al (2018) Anticoagulation for perioperative thromboprophylaxis in people with cancer. Cochrane Database Syst Rev 7(7):CD009447","journal-title":"Cochrane Database Syst Rev"},{"key":"2872_CR60","doi-asserted-by":"publisher","first-page":"1165437","DOI":"10.3389\/fonc.2023.1165437","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang L, Su Z, Xie C, Li R, Pan W, Xu L et al (2023) Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study. Front Oncol 13:1165437","journal-title":"Front Oncol"},{"issue":"11","key":"2872_CR61","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/iju.13189","volume":"23","author":"K Hata","year":"2016","unstructured":"Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T et al (2016) Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: a prospective randomized clinical trial. Int J Urol 23(11):923\u2013928","journal-title":"Int J Urol"},{"key":"2872_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.thromres.2018.04.001","volume":"166","author":"J Song","year":"2018","unstructured":"Song J, Xuan L, Wu W, Shen Y, Tan L, Zhong M (2018) Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: a randomized controlled trial. Thromb Res 166:22\u201327","journal-title":"Thromb Res"},{"issue":"6","key":"2872_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7410","volume":"3","author":"SR Guntupalli","year":"2020","unstructured":"Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM et al (2020) Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 3(6):e207410","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2872_CR64","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s11605-018-3936-1","volume":"23","author":"MF Rashid","year":"2019","unstructured":"Rashid MF, Jackson TL, Morgan JA, Dwyer FA, Schrope BA, Chabot JA et al (2019) Dabigatran (Pradaxa) is safe for extended venous thromboembolism prophylaxis after surgery for pancreatic cancer. J Gastrointest Surg 23(6):1166\u20131171","journal-title":"J Gastrointest Surg"},{"key":"2872_CR65","doi-asserted-by":"crossref","unstructured":"Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, Kawamura Suguiura GY, Cioni CH et al (2022) Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost 28:10760296221132556","DOI":"10.1177\/10760296221132556"},{"issue":"2","key":"2872_CR66","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1136\/ijgc-2020-001991","volume":"31","author":"S Bisch","year":"2021","unstructured":"Bisch S, Findley R, Ince C, Nardell M, Nelson G (2021) Efficacy of pre-operative pharmacologic thromboprophylaxis on incidence of venous thromboembolism following major gynecologic and gynecologic oncology surgery: a systematic review and meta-analysis. Int J Gynecol Cancer 31(2):257\u2013264","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"2872_CR67","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","volume":"346","author":"D Bergqvist","year":"2002","unstructured":"Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975\u2013980","journal-title":"N Engl J Med"},{"issue":"4","key":"2872_CR68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","volume":"259","author":"MC Vedovati","year":"2014","unstructured":"Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R et al (2014) A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg 259(4):665\u2013669","journal-title":"Ann Surg"},{"key":"2872_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.thromres.2021.06.010","volume":"204","author":"W Knoll","year":"2021","unstructured":"Knoll W, Fergusson N, Ivankovic V, Wang TF, Caiano L, Auer R et al (2021) Extended thromboprophylaxis following major abdominal\/pelvic cancer-related surgery: a systematic review and meta-analysis of the literature. Thromb Res 204:114\u2013122","journal-title":"Thromb Res"},{"issue":"10","key":"2872_CR70","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943\u2013949","journal-title":"Lancet Oncol"},{"issue":"7","key":"2872_CR71","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601\u2013609","journal-title":"N Engl J Med"},{"issue":"9","key":"2872_CR72","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283\u20131292","journal-title":"Eur J Cancer"},{"issue":"18","key":"2872_CR73","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S et al (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 33(18):2028\u20132034","journal-title":"J Clin Oncol"},{"issue":"8","key":"2872_CR74","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728","journal-title":"N Engl J Med"},{"issue":"8","key":"2872_CR75","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711\u2013719","journal-title":"N Engl J Med"},{"issue":"12","key":"2872_CR76","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/jth.14613","volume":"17","author":"A Li","year":"2019","unstructured":"Li A, Kuderer NM, Garcia DA, Khorana AA, Wells PS, Carrier M et al (2019) Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. J Thromb Haemost 17(12):2141\u20132151","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2872_CR77","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729\u20131735","journal-title":"Arch Intern Med"},{"issue":"2","key":"2872_CR78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146\u2013153","journal-title":"N Engl J Med"},{"issue":"12","key":"2872_CR79","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062\u20131072","journal-title":"Am J Med"},{"issue":"4","key":"2872_CR80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1076029606293692","volume":"12","author":"SR Deitcher","year":"2006","unstructured":"Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389\u2013396","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"2872_CR81","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677\u2013686","journal-title":"JAMA"},{"issue":"1","key":"2872_CR82","first-page":"CD006649","volume":"1","author":"MB Hakoum","year":"2018","unstructured":"Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I et al (2018) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 1(1):CD006649","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2872_CR83","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187\u20132191","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2872_CR84","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37-46","journal-title":"Lancet Haematol"},{"issue":"7","key":"2872_CR85","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129(7):764\u2013772","journal-title":"Circulation"},{"issue":"7","key":"2872_CR86","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"20","key":"2872_CR87","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"key":"2872_CR88","doi-asserted-by":"publisher","unstructured":"Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Sudhoff T et al (2025) CONKO-011\/AIO-SUP-0115\/ass.: rivaroxaban compared to low molecular weight heparin in cancer patients with acute venous thromboembolism. Oncol Res Treat\u00a0;48(11):685\u2013695. https:\/\/doi.org\/10.1159\/000545976","DOI":"10.1159\/000545976"},{"issue":"3","key":"2872_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahe I et al (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 161(3):781\u2013790","journal-title":"Chest"},{"issue":"8","key":"2872_CR90","doi-asserted-by":"publisher","first-page":"e12604","DOI":"10.1002\/rth2.12604","volume":"5","author":"A Maraveyas","year":"2021","unstructured":"Maraveyas A, Beyer-Westendorf J, Lee AY, Mantovani LG, De Sanctis Y, Abdelgawwad K et al (2021) Cancer-Associated ThrOmboSIs - Patient-Reported OutcoMes With RivarOxaban (COSIMO) - baseline characteristics and clinical outcomes. Res Pract Thromb Haemost 5(8):e12604","journal-title":"Res Pract Thromb Haemost"},{"key":"2872_CR91","doi-asserted-by":"publisher","first-page":"1049283","DOI":"10.3389\/fphar.2022.1049283","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Wang L, Li H, Huang W, Zhao L, Guo W (2022) Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: an updated traditional and Bayesian network meta-analysis. Front Pharmacol 13:1049283","journal-title":"Front Pharmacol"},{"issue":"2","key":"2872_CR92","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2872_CR93","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"issue":"14","key":"2872_CR94","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mahe","year":"2025","unstructured":"Mahe I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N et al (2025) Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 392(14):1363\u20131373","journal-title":"N Engl J Med"},{"key":"2872_CR95","doi-asserted-by":"publisher","unstructured":"Ghorbanzadeh A, Porres-Aguilar M, McBane R, Gerotziafas G, Tafur A (2025) Extended anticoagulation in patients with cancer-associated venous thromboembolism. Pol Arch Intern Med 135(6):17025. https:\/\/doi.org\/10.20452\/pamw","DOI":"10.20452\/pamw"},{"key":"2872_CR96","doi-asserted-by":"publisher","first-page":"109500","DOI":"10.1016\/j.thromres.2025.109500","volume":"255","author":"Z Wang","year":"2025","unstructured":"Wang Z, Yu Z, Niu T (2025) Prolonged duration of pharmacological thromboprophylaxis following oncologic surgery: a systematic review and meta-analysis of RCTs. Thromb Res 255:109500","journal-title":"Thromb Res"},{"issue":"21","key":"2872_CR97","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.123.066360","volume":"148","author":"Y Yamashita","year":"2023","unstructured":"Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D et al (2023) Edoxaban for 12 months versus 3 months in patients with cancer with isolated distal deep vein thrombosis (ONCO DVT study): an open-label, multicenter, randomized clinical trial. Circulation 148(21):1665\u20131676","journal-title":"Circulation"},{"issue":"9","key":"2872_CR98","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.124.072758","volume":"151","author":"Y Yamashita","year":"2025","unstructured":"Yamashita Y, Morimoto T, Muraoka N, Shioyama W, Chatani R, Shibata T et al (2025) Rivaroxaban for 18 months versus 6 months in patients with cancer and acute low-risk pulmonary embolism: an open-label, multicenter, randomized clinical trial (ONCO PE trial). Circulation 151(9):589\u2013600","journal-title":"Circulation"},{"issue":"1","key":"2872_CR99","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/S2352-3026(25)00291-1","volume":"13","author":"I Mahe","year":"2026","unstructured":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM et al (2026) Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol 13(1):e41\u2013e48","journal-title":"Lancet Haematol"},{"issue":"2","key":"2872_CR100","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","volume":"94","author":"I Kopolovic","year":"2015","unstructured":"Kopolovic I, Lee AY, Wu C (2015) Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 94(2):329\u2013336","journal-title":"Ann Hematol"},{"issue":"2","key":"2872_CR101","first-page":"170","volume":"20","author":"K Kilpatrick","year":"2021","unstructured":"Kilpatrick K, Shaw JL, Jaramillo R, Toler A, Eisen M, Sangare L et al (2021) Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials. Clin Colorectal Cancer 20(2):170\u2013176","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"2872_CR102","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jth.14015","volume":"16","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C et al (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16(6):1246\u20131249","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2872_CR103","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.acvd.2023.11.006","volume":"117","author":"L Bertoletti","year":"2024","unstructured":"Bertoletti L, Girard P, Elias A, Espitia O, Schmidt J, Couturaud F et al (2024) Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment. Arch Cardiovasc Dis 117(1):84\u201393","journal-title":"Arch Cardiovasc Dis"},{"key":"2872_CR104","doi-asserted-by":"crossref","unstructured":"Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY; Subcommittee on H et al (2013) Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 11(9):1760\u20131765","DOI":"10.1111\/jth.12338"},{"issue":"5","key":"2872_CR105","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1055\/s-0041-1735194","volume":"122","author":"G Agnelli","year":"2022","unstructured":"Agnelli G, Munoz A, Franco L, Mahe I, Brenner B, Connors JM et al (2022) Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 122(5):796\u2013807","journal-title":"Thromb Haemost"},{"issue":"4","key":"2872_CR106","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/apm-22-1203","volume":"12","author":"H Otani","year":"2023","unstructured":"Otani H, Amano K, Morita T, Miura T, Mori N, Tatara R et al (2023) Difficulty swallowing and food bolus obstruction in advanced cancer: association with the cachexia-related quality of life. Ann Palliat Med 12(4):717\u2013728","journal-title":"Ann Palliat Med"},{"issue":"6","key":"2872_CR107","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","volume":"43","author":"L Girardi","year":"2023","unstructured":"Girardi L, Wang TF, Ageno W, Carrier M (2023) Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism. Arterioscler Thromb Vasc Biol 43(6):824\u2013831","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"2872_CR108","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.thromres.2021.11.026","volume":"213","author":"TF Wang","year":"2022","unstructured":"Wang TF (2022) Drug-drug interactions: implications for anticoagulation, with focus in patients with cancer. Thromb Res 213(Suppl 1):S66\u2013S71","journal-title":"Thromb Res"},{"key":"2872_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-025-01144-z","author":"D Capodanno","year":"2025","unstructured":"Capodanno D, Alexander JH, Bahit MC, Eikelboom JW, Gibson CM, Goodman SG et al (2025) Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-025-01144-z","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"2872_CR110","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S et al (2023) Pharmacology and clinical development of factor XI inhibitors. Circulation 147(11):897\u2013913","journal-title":"Circulation"},{"issue":"1","key":"2872_CR111","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","volume":"22","author":"J Mader","year":"2024","unstructured":"Mader J, Rolling CC, Voigtlander M, Schulenkorf A, Lehr C, Regenhardt J et al (2024) Effect of factor XI inhibition on tumor cell-induced coagulation activation. J Thromb Haemost 22(1):199\u2013212","journal-title":"J Thromb Haemost"},{"key":"2872_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.030","author":"P Chrysafi","year":"2025","unstructured":"Chrysafi P, Derkach A, Xirou V, Fenelus M, Patell R, Zwicker JI et al (2025) Venous thromboembolism in patients with cancer and factor XI deficiency. J Thromb Haemost. https:\/\/doi.org\/10.1016\/j.jtha.2025.06.030","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2872_CR113","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1056\/NEJMe2414209","volume":"392","author":"DJ Angiolillo","year":"2025","unstructured":"Angiolillo DJ, Capodanno D (2025) Uncoupling thrombosis and hemostasis by inhibiting factor XI. N Engl J Med 392(4):400\u2013403","journal-title":"N Engl J Med"},{"key":"2872_CR114","unstructured":"ClinicalTrials.gov UNLoM. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05171049"},{"key":"2872_CR115","unstructured":"ClinicalTrials.gov UNLoM. 2024. Available from:  https:\/\/clinicaltrials.gov\/study\/NCT05171075"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02872-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:02:48Z","timestamp":1771318968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02872-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":115,"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02872-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DC declares lecture fees from Daiichi Sankyo and Sanofi. All other authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}